Table 1.

Study population baseline characteristics.

Parameter		Value
N		192
Age (years), mean (SD)		64.1 (9.1)
Sex, n (%)	Male	114 (59.4)
Race, n (%)	White	183 (95.3)
	Asian	8 (4.2)
	Black	1 (0.5)
PD duration (years), mean (SD)		12.4 (5.8)
Taking levodopa or derivatives, n (%)	Alone	53 (27.6)
	With 1 other PD drug	62 (32.3)
	Dopamine-agonists	33 (17.2)
	COMT-inhibitors	18 (9.4)
	Amantadine derivatives	8 (4.2)
	MAO-B inhibitors	2 (1.0)
	With 2 other PD drugs	46 (24.0)
	Dopamine-agonists	38 (19.8)
	COMT-inhibitors	24 (12.5)
	Amantadine derivatives	21 (10.9)
	MAO-B inhibitors	5 (2.6)
	With≥ 3 other PD drugs	31 (16.1)
	Dopamine-agonists	29 (15.1)
	COMT-inhibitors	19 (9.9)
	Amantadine derivatives	26 (13.5)
	MAO-B inhibitors	13 (6.8)
Mini-Mental State Exam score, mean (SD)		28.5 (1.7)